296 related articles for article (PubMed ID: 34068643)
1. Emerging Roles of SKP2 in Cancer Drug Resistance.
Wu T; Gu X; Cui H
Cells; 2021 May; 10(5):. PubMed ID: 34068643
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
[TBL] [Abstract][Full Text] [Related]
3. Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer.
Davidovich S; Ben-Izhak O; Shapira M; Futerman B; Hershko DD
Breast Cancer Res; 2008; 10(4):R63. PubMed ID: 18644126
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.
Huang KT; Pavlides SC; Lecanda J; Blank SV; Mittal KR; Gold LI
PLoS One; 2012; 7(9):e46072. PubMed ID: 23029392
[TBL] [Abstract][Full Text] [Related]
5. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
Chen Q; Xie W; Kuhn DJ; Voorhees PM; Lopez-Girona A; Mendy D; Corral LG; Krenitsky VP; Xu W; Moutouh-de Parseval L; Webb DR; Mercurio F; Nakayama KI; Nakayama K; Orlowski RZ
Blood; 2008 May; 111(9):4690-9. PubMed ID: 18305219
[TBL] [Abstract][Full Text] [Related]
6. The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
Jamal A; Swarnalatha M; Sultana S; Joshi P; Panda SK; Kumar V
Cell Cycle; 2015; 14(16):2688-700. PubMed ID: 26038816
[TBL] [Abstract][Full Text] [Related]
7. Skp2 regulates G2/M progression in a p53-dependent manner.
Hu R; Aplin AE
Mol Biol Cell; 2008 Nov; 19(11):4602-10. PubMed ID: 18716061
[TBL] [Abstract][Full Text] [Related]
8. Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop.
Fan X; Wang Y; Fan J; Chen R
J Cell Biochem; 2019 Jun; 120(6):10643-10651. PubMed ID: 30672020
[TBL] [Abstract][Full Text] [Related]
9. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.
Ungermannova D; Lee J; Zhang G; Dallmann HG; McHenry CS; Liu X
J Biomol Screen; 2013 Sep; 18(8):910-20. PubMed ID: 23589337
[TBL] [Abstract][Full Text] [Related]
10. SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer.
Fagan-Solis KD; Pentecost BT; Gozgit JM; Bentley BA; Marconi SM; Otis CN; Anderton DL; Schneider SS; Arcaro KF
J Cell Physiol; 2014 Sep; 229(9):1160-9. PubMed ID: 24443386
[TBL] [Abstract][Full Text] [Related]
11. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase.
Li P; Li C; Zhao X; Zhang X; Nicosia SV; Bai W
J Biol Chem; 2004 Jun; 279(24):25260-7. PubMed ID: 15075339
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics and chemical library screens reveal a novel SCF
Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
[TBL] [Abstract][Full Text] [Related]
13. Specific small molecule inhibitors of Skp2-mediated p27 degradation.
Wu L; Grigoryan AV; Li Y; Hao B; Pagano M; Cardozo TJ
Chem Biol; 2012 Dec; 19(12):1515-24. PubMed ID: 23261596
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase.
Hao B; Zheng N; Schulman BA; Wu G; Miller JJ; Pagano M; Pavletich NP
Mol Cell; 2005 Oct; 20(1):9-19. PubMed ID: 16209941
[TBL] [Abstract][Full Text] [Related]
15. Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade.
Mickova A; Kharaishvili G; Kurfurstova D; Gachechiladze M; Kral M; Vacek O; Pokryvkova B; Mistrik M; Soucek K; Bouchal J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799604
[TBL] [Abstract][Full Text] [Related]
16. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.
Clement E; Inuzuka H; Nihira NT; Wei W; Toker A
Sci Signal; 2018 Mar; 11(521):. PubMed ID: 29535262
[TBL] [Abstract][Full Text] [Related]
17. A signal transduction pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its correlation with progression in human melanoma.
Qu X; Shen L; Zheng Y; Cui Y; Feng Z; Liu F; Liu J
J Invest Dermatol; 2014 Jan; 134(1):159-167. PubMed ID: 23792459
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells.
Bar-On O; Shapira M; Hershko DD
Anticancer Drugs; 2007 Nov; 18(10):1113-21. PubMed ID: 17893511
[TBL] [Abstract][Full Text] [Related]
19. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.
Shapira M; Kakiashvili E; Rosenberg T; Hershko DD
Breast Cancer Res; 2006; 8(4):R46. PubMed ID: 16859513
[TBL] [Abstract][Full Text] [Related]
20. SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.
Bretones G; Acosta JC; Caraballo JM; Ferrándiz N; Gómez-Casares MT; Albajar M; Blanco R; Ruiz P; Hung WC; Albero MP; Perez-Roger I; León J
J Biol Chem; 2011 Mar; 286(11):9815-25. PubMed ID: 21245140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
